While many many Japanese firms have shifted much of their commercial and R&D focus to the US, several have recently faced development setbacks that could affect their mid-term outlook in this huge market.
Nippon Shinyaku Co., Ltd.’s Duchenne muscular dystrophy (DMD) therapeutic Viltepso (viltolarsen) recently missed its primary efficacy endpoint in preliminary...